FILTER
FILTERED INTERVIEW RESULTS
Roberto Santos
CEO, UNIGEL
Unigel explains the impact of COVID-19 on Brazil’s chemical sector and why there is confidence that the industry is recovering.
Michael Bennett
PRESIDENT & CEO, ALTAMIRA GOLD
Altamira is making the transition from an exploration to a production company at the perfect time for the price of gold, and an opportune time in Brazil – a pro-mining country that has streamlined its permitting processes.
Martin Sack
REGIONAL HEAD AMERICAS, LESCHACO
Leschaco is a freight forwarder expanding its’ services and network across the Americas.
Jan Krueder & Matthias Vorbeck
CEO, QUÍMICA ANASTACIO & GENERAL MANAGER, ANASTACIO OVERSEAS
Chemical distributer Anastacio sees opportunities for growth across Latin America.
Marcos De Marchi
CEO, ELEKEIROZ
Elekeiroz speaks to GBR about the market conditions for petrochemicals in Brazil and how reforms can help the industry.
Edison Terra
VICE PRESIDENT OF OLEFINS AND POLYOLEFINS UNIT FOR SOUTH AMERICA, BRASKEM
Braskem is the largest petrochemical company in the Americas, the largest producer of polypropylene in the US, and a global leader in biopolymers production.
Jorge Buckup
PRESIDENT LATIN AMERICA, UNIVAR SOLUTIONS
Univar Solutions consolidates in the wider region through the Nexeo acquisition.
Fabiano Machion
GENERAL MANAGER SOUTH AMERICA, NEWPORT TANK
Newport Tank was acquired by Shanghai Junzheng Logistics, and will adapt its strategy with an eye to the future.
Jarl Kåreson Hakvåg
CHARTERING SOUTH AMERICA AC/USG, ODFJELL TANKERS
Odfjell is the second largest specialized tanker company for chemical transportation in the world.
Dennys Spencer
DIRECTOR, AMBIPAR RESPONSE
Ambipar Response is expanding its Latin American presence.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
